Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Doctors' teamwork under the microscope: can better meetings lead to better cancer care?

NCT ID NCT07645716

Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how doctors in tumor board meetings work together when discussing ovarian and uterine cancer cases. About 400 physicians will fill out surveys after each meeting to measure things like communication, teamwork, and decision-making. The goal is to understand what makes these meetings effective, which could improve how cancer treatment plans are made.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal how team communication and collaboration affect cancer treatment decisions, potentially improving patient care.
What could go wrong
This is an observational study with no treatment given, so it won't directly change patient outcomes. Results may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Physicians participating in ovarian and uterine cancer multidisciplinary tumor board meetings at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, either in person or online, who are involved in the clinical decision-making process during the study period.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Physicians participating in the clinical decision-making process within ovarian and uterine cancer multidisciplinary tumor board meetings. * Participation in the full tumor board session. * Participation either in person or online. * Representation of at least one relevant specialty or role involved in the clinical decision-making process. Exclusion Criteria: * Partial attendance at the ovarian and uterine cancer multidisciplinary tumor board session. * Trainees or other attendees not directly involved in the clinical decision-making process. * Physicians whose specialty contribution consists of occasional consultation for less than 50% of the study period. * Incomplete survey completion. * If more than one member represents the same specialty or role, participants with lower participation in the clinical decision-making process may be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian neoplasm tumor of uterus uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian neoplasms Uterine neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica

    Roma, Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.